Coherus BioSciences, Inc. (CHRS)
NASDAQ: CHRS · IEX Real-Time Price · USD
1.640
+0.070 (4.46%)
At close: Jul 19, 2024, 12:00 AM
1.670
+0.030 (1.83%)
Pre-market: Jul 22, 2024, 9:16 AM EDT
Coherus BioSciences Employees
Coherus BioSciences had 306 employees as of December 31, 2023. The number of employees decreased by 53 or -14.76% compared to the previous year.
Employees
306
Change (1Y)
-53
Growth (1Y)
-14.76%
Revenue / Employee
$986,507
Profits / Employee
-$193,752
Market Cap
188.15M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Accuray | 1,024 |
Metagenomi | 236 |
Puma Biotechnology | 185 |
Rani Therapeutics Holdings | 140 |
Adverum Biotechnologies | 121 |
Biomea Fusion | 103 |
MediWound | 100 |
Fennec Pharmaceuticals | 29 |
CHRS News
- 25 days ago - Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All Cash Transaction - GlobeNewsWire
- 7 weeks ago - Coherus Management to Present at the 2024 Jefferies Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine receptor 8 (CCR8) Antibody, CHS-114, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - GlobeNewsWire
- 2 months ago - Coherus Management to Present at the TD Cowen 5th Annual Oncology Innovation Virtual Summit: Insights for ASCO & EHA - GlobeNewsWire
- 2 months ago - Coherus BioSciences Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan - GlobeNewsWire
- 2 months ago - Coherus Announces Clinical Collaboration with the Cancer Research Institute for a Novel Combination Evaluating LOQTORZI® (toripalimab-tpzi) with ENB Therapeutics' ENB-003 for the Treatment of Ovarian Cancer - GlobeNewsWire
- 2 months ago - Coherus to Report First Quarter 2024 Financial Results on May 9, 2024 - GlobeNewsWire